CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer

Table 1

Completed clinical trial of HDAC inhibitors in breast cancer. CR: complete response; PR: partial response; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; AEs: adverse events; TTP: time to disease progression; TTF: time to treatment failure; DoR: duration of response.

No.	NCT number	Interventions	Phases	Enrollment	Status	Outcome
1	NCT00395655	Hydralazine and magnesium valproate	Phase 2	16	Terminated	CR: 31% (5/16); PR: 50% (8/16)
2	NCT01194908	Decitabine, LBH589, and tamoxifen	Phase 1, phase 2	5	Terminated	No study results posted
3	NCT00567879	Panobinostat and Trastuzumab	Phase 1, phase 2	56	Terminated	PR: 1.78% (1/56)
4	NCT00777335	Panobinostat and LBH589	Phase 2	4	Terminated	CR: 0; PR: 0
5	NCT00132002	Vorinostat	Phase 2	14	Terminated	ORR: 0; mean OS: 24 months
6	NCT00262834	Vorinostat	Phase 2	54	Completed	Number of participants with AEs: 17/25
7	NCT01118975	Vorinostat and lapatinib	Phase 1, phase 2	12	Terminated	No study results posted
8	NCT00828854	Entinostat (SNDX-275)	Phase 2	25	Completed	No study results posted
9	NCT00258349	Vorinostat and trastuzumab	Phase 1, phase 2	16	Completed	CR: 0; PR: 0; mean TTP: 1.5 months. Mean OS: 9.3 months
10	NCT00365599	Vorinostat and tamoxifen	Phase 2	43	Completed	ORR: 18.6% (8/43); mean TTP: 10.3 months. Number of participants with serious AEs: 4/43
11	NCT00676663	Entinostat and exemestane	Phase 2	64	Completed	ORR: 4.7%
12	NCT01194427	Vorinostat and tamoxifen	Phase 2	2	Terminated	No study results posted
13	NCT00126451	MK0683, vorinostat, and suberoylanilide hydroxamic acid (SAHA)	Phase 2	16	Terminated	TTP: 33.5 days. Number of participants with serious AEs: 11/16
14	NCT01105312	Letrozole and panobinostat	Phase 1, phase 2	28	Completed	CR: 0; PR: 0; mean survival time: 16.1 months; mean TTP: 2.1 months; PFS: 2.1 months; TTF: 2.1 months
15	NCT00368875	Vorinostat, paclitaxel, and bevacizumab	Phase 1, phase 2	53	Completed	CR: 4% (2/53); PR: 45% (24/53); mean PFS: 11.9 months; mean OS: 29.4 months; TTF: 0
16	NCT01234532	Entinostat and anastrozole	Phase 2	5	Terminated	No study results posted
17	NCT00574587	Vorinostat, paclitaxel, trastuzumab, doxorubicin, and cyclophosphamide	Phase 1, phase 2	55	Completed	CR: 33.3% (17/51)
18	NCT00777049	Panobinostat	Phase 2	54	Completed	CR: (1.9%) 1/54; PR: (1.9%) 1/54
19	NCT02395627	Tamoxifen, vorinostat, and pembrolizumab	Phase 2	38	Terminated	ORR: 6.67%; DoR: 17.0 months (group A), 8.8 months (group B); mean PFS: 2.57 months (group A), 2.63 months (group B); mean OS: 14.3 months (group A), 15.0 months (group B), and 7.8 months (group C)